Does the preventive effect of different drugs depend on location of the atherosclerotic process?

International Angiology

Volumn 27, Issue 4, 2008, Pages 274-280

  Poredoš, Pavel ^a   Jeiovnik M K ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Atherosclerosis; Cerebrovascular accidents; Coronary artery disease; Peripheral vascular diseases; Prevention and control; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; SULFONYLUREA;

ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DRUG COST; DRUG DOSE REGIMEN; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; REVIEW; RISK FACTOR; STROKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 50049096204     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
2. Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, Brown T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischemia (Lis). Int Angiol 2000;19:97-125.
3. Blinc A, Poredoš P. Pharmacological prevention of athero-thrombotic events in patients with peripheral arterial disease. Eur J Clin Invest 2007;37:157-64.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. CAPRIE Steering Committee. A randomised, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996;348:1329-39.
6. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
8. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
9. Gould AL, Rossouw SE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-52.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
11. Sever PS, Bjorn-Dahlof, Neil R, Poulter NR, Wedel H, Beevers G et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTTLLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58.
12. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke 2004;35:2902-9.
13. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
14. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001;19:1139-47.
15. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischaemic attack. N Engl J Med 2006;355:459-59.
16. Menotti A, Keysa A, Blackburn H, Aravanis C, Dontas A, Fidanza F et al. Twenty-year stroke-mortality and prediction in twelve cohorts of the Seven Countries Study. Int J Epidemiol 1990;19:309-15.
17. Blankenhorn DH, Zen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH et al. Effect of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-47.
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
19. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias. N Engl J Med 1990;323:946-55.
20. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-5.
21. Mohler ER, Hiatt WR, Creager MA. Cholestesrol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-6.
22. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-64.
23. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45.
24. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44.
25. Radack K, Deck C. Beta-adrenergic blocker therapy does not women intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trial. Arch Intern Med 1991;151:1769-76.
26. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002;62:1381-405.
27. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
28. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
29. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362: 782-8.
30. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
31. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
32. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
33. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trials. Am J Cardiol 1995;75:894-903.
34. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med 2005;353:2643-53.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
36. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharett AR. HbA1c and peripheral arterial disease in diabetes. The Atherosclerosis Risk in Communities Study. Diabetes Care 2006;29:877-82.
37. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006;29:S4-S42.